Pfizer has exceeded second-quarter earnings and revenue estimates, prompting an upward revision of its full-year revenue outlook. This positive performance is largely attributed to strong sales from key non-COVID-19 products like Eliquis, which significantly outperformed expectations.
While the company lowered its COVID-19 product revenue forecast, it reaffirmed its profit guidance and announced substantial cost-saving initiatives, signaling a strategic focus on pipeline development and future growth drivers.
Pharma giant Pfizer Inc. (PFE) has announced its second-quarter financial results, demonstrating a robust performance that exceeded Wall Street expectations. The company has also revised its full-year revenue guidance upwards, primarily driven by the exceptional sales of its non-COVID-19 products, notably the blood thinner Eliquis and the targeted cancer drug Padcev.
Pfizer's updated full-year revenue projection now stands between $60.5 billion and $62.5 billion, an increase from its previous outlook of $59.5 billion to $62.5 billion. This revised range suggests that the company's overall revenue may remain relatively flat or see a slight decrease compared to the $62.6 billion recorded in 2025.
The company has adjusted its revenue forecast for its COVID-19 portfolio, including the vaccine Comirnaty and the antiviral pill Paxlovid, to $4 billion, down from the earlier estimate of approximately $5 billion. This recalibration reflects anticipated lower utilization of Paxlovid due to reduced COVID-19 incidence and a projected concentration of Comirnaty sales towards the year-end vaccination season, as explained by Pfizer's interim CFO, Cecile Guegan.
Despite the adjustments in COVID-19 product revenue, Pfizer reaffirmed its full-year adjusted profit guidance, expecting earnings per share to be between $2.80 and $3.00.
In a move to enhance financial efficiency, Pfizer also revealed additional cost-saving measures, targeting $2.5 billion in savings through two distinct cost-cutting programs. These savings are slated to be realized between 2027 and 2029.
CEO Albert Bourla expressed confidence in the company's business trajectory, stating, "With our strong performance through the first half of the year and our ongoing productivity enhancement discipline, we remain confident in our business."
Second-Quarter Performance Highlights:
- Adjusted Earnings Per Share (EPS): 77 cents, surpassing the analyst consensus of 68 cents.
- Revenue: $15.03 billion, exceeding the expected $14.41 billion.
The reported revenue of $15.03 billion marks a 3% increase year-over-year. Significant contributions from Eliquis, which generated $2.43 billion in sales (a 19% increase and exceeding analyst expectations of $2.08 billion), and Padcev were instrumental in offsetting the decline in COVID-19 related sales. Recently introduced and acquired products added $3.2 billion to the quarter's revenue.
Pfizer reported a net loss of $248 million, or 4 cents per share, for the quarter. This was largely due to a $4.3 billion non-cash impairment charge stemming from reduced revenue expectations for certain products. These reductions were influenced by disappointing late-stage trial results for sigvotatug vedotin in non-small-cell lung cancer and the removal of revenue projections for the sickle cell disease drug Oxbryta, which has been withdrawn from the market.
Excluding specific charges, adjusted EPS stood at 77 cents per share. The company is also implementing a multiyear initiative aimed at cutting costs, with the first phase targeting $1.5 billion in savings by the end of 2027. A second phase of a separate cost-cutting program is expected to yield an additional $1 billion in savings from 2027 to 2029, adding to previously announced savings.
Looking ahead, Pfizer is focusing on long-term pipeline investments, including its recent $10 billion acquisition of obesity biotech Metsera, to navigate the decline in COVID-19 product sales and the impact of sales from older drugs. Investors are keenly awaiting further data releases from Pfizer, particularly concerning its GLP-1 injection and amylin asset combination therapy.
